{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:39:01Z","timestamp":1786981141875,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04043-5","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:52:29Z","timestamp":1773996749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression"],"prefix":"10.1007","volume":"46","author":[{"given":"Yousef Mesaed","family":"Al-Shammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef M.","family":"AlDhafiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Kamal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel Bader","family":"Alkharraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ahmad","family":"Al-Awadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed Mesaed","family":"Alnabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"4043_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"4043_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144\u20131167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"4043_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"J Ambati","year":"2012","unstructured":"Ambati J, Fowler BJ (2012) Mechanisms of age-related macular degeneration. Neuron 75:26\u201339. https:\/\/doi.org\/10.1016\/j.neuron.2012.06.018","journal-title":"Neuron"},{"key":"4043_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487. https:\/\/doi.org\/10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"key":"4043_CR5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A et al (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120:844\u2013851. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.036","journal-title":"Ophthalmology"},{"key":"4043_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100852","volume":"35","author":"AP Marques","year":"2021","unstructured":"Marques AP, Ramke J, Cairns J et al (2021) Global economic productivity losses from vision impairment and blindness. EClinicalMedicine 35:100852. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100852","journal-title":"EClinicalMedicine"},{"key":"4043_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS et al (2019) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"4043_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237:185\u2013222. https:\/\/doi.org\/10.1159\/000458539","journal-title":"Ophthalmologica"},{"key":"4043_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA et al (2019) Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol 4:e000398. https:\/\/doi.org\/10.1136\/bmjophth-2019-000398","journal-title":"BMJ Open Ophthalmol"},{"key":"4043_CR10","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.21873\/anticanres.13552","volume":"39","author":"J Giuliani","year":"2019","unstructured":"Giuliani J, Bonetti A (2019) The economic impact of biosimilars in oncology and hematology: the case of Trastuzumab and Rituximab. Anticancer Res 39:3971\u20133973. https:\/\/doi.org\/10.21873\/anticanres.13552","journal-title":"Anticancer Res"},{"key":"4043_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","volume":"104","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD et al (2020) Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol 104:2\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314443","journal-title":"Br J Ophthalmol"},{"key":"4043_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4043_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2023.101484","volume":"25","author":"M Prasad","year":"2024","unstructured":"Prasad M (2024) Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Glob Health 25:101484. https:\/\/doi.org\/10.1016\/j.cegh.2023.101484","journal-title":"Clin Epidemiol Glob Health"},{"key":"4043_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","volume":"139","author":"SJ Woo","year":"2021","unstructured":"Woo SJ, Veith M, Hamouz J et al (2021) Efficacy and safety of a proposed Ranibizumab biosimilar product vs a reference Ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 139:68\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053","journal-title":"JAMA Ophthalmol"},{"key":"4043_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40123-023-00836-4","volume":"13","author":"B Li","year":"2024","unstructured":"Li B, Fan K, Zhang T et al (2024) Efficacy and safety of biosimilar QL1207 vs. the reference Aflibercept for patients with neovascular age-related macular degeneration: a randomized Phase 3 trial. Ophthalmol Ther 13:353\u2013366. https:\/\/doi.org\/10.1007\/s40123-023-00836-4","journal-title":"Ophthalmol Ther"},{"key":"4043_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001561","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Sadda SVR, Bradvica M et al (2023) Biosimilar SB15 versus reference Aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. BMJ Open Ophthalmol. https:\/\/doi.org\/10.1136\/bmjophth-2023-001561","journal-title":"BMJ Open Ophthalmol"},{"key":"4043_CR17","doi-asserted-by":"publisher","unstructured":"Loewenstein A, Czumbel N, Ernest J, Dusov\u00e1 J, Pearlman J, Nowosielska A (2023) Randomized trial of biosimilar XSB-001 versus reference Ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmol Retina 7(9):753\u2013761. https:\/\/doi.org\/10.1016\/j.oret.2023.05.005","DOI":"10.1016\/j.oret.2023.05.005"},{"key":"4043_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65815-6","author":"SW Kang","year":"2024","unstructured":"Kang SW, Choi J, Sheth VS et al (2024) Comparison of the efficacy and safety of SCD411 and reference Aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-65815-6","journal-title":"Sci Rep"},{"key":"4043_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275611","author":"CK Yoon","year":"2022","unstructured":"Yoon CK, Oh J, Bae K et al (2022) Efficacy and safety of a new Ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0275611","journal-title":"PLoS ONE"},{"key":"4043_CR20","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","volume":"70","author":"R Singh","year":"2022","unstructured":"Singh R, Chauhan R, Saxena A et al (2022) A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin\u2019s Ranibizumab with Lucentis \u00ae in patients with neovascular age-related macular degeneration. Indian J Ophthalmol 70:3008\u20133014. https:\/\/doi.org\/10.4103\/ijo.IJO_2118_21","journal-title":"Indian J Ophthalmol"},{"key":"4043_CR21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","volume":"44","author":"AF Bordon","year":"2024","unstructured":"Bordon AF, Kaiser PK, Wolf A et al (2024) Efficacy and safety of the proposed biosimilar Aflibercept, SDZ-AFL, in patients with neovascular age-related macular degeneration: 52-week results from the phase 3 mylight study. Retina 44:1704\u20131713. https:\/\/doi.org\/10.1097\/IAE.0000000000004174","journal-title":"Retina"},{"key":"4043_CR22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2024.02.012","volume":"8","author":"R Karkhaneh","year":"2024","unstructured":"Karkhaneh R, Faghihi H, Riazi-Esfahani H et al (2024) Evaluating the efficacy and safety of Aflibercept biosimilar (P041) compared with originator product in patients with neovascular age-related macular degeneration. Ophthalmol Retina 8:744\u2013753. https:\/\/doi.org\/10.1016\/j.oret.2024.02.012","journal-title":"Ophthalmol Retina"},{"key":"4043_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14712598.2025.2519531","volume":"25","author":"H Agostini","year":"2025","unstructured":"Agostini H, Baumane K, Bal\u010di\u016bnien\u0117 VJ et al (2025) A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product Aflibercept in participants with neovascular age-related macular degeneration. Expert Opin Biol Ther 25:773\u2013787. https:\/\/doi.org\/10.1080\/14712598.2025.2519531","journal-title":"Expert Opin Biol Ther"},{"key":"4043_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40123-024-00883-5","volume":"13","author":"AK Ghosh","year":"2024","unstructured":"Ghosh AK, Nikumbh US, Shukla CK et al (2024) Efficacy, safety and immunogenicity of Sun\u2019s Ranibizumab biosimilar in neovascular age-related macular degeneration: a phase 3, double-blind comparative study. Ophthalmol Ther 13:1369\u20131382. https:\/\/doi.org\/10.1007\/s40123-024-00883-5","journal-title":"Ophthalmol Ther"},{"key":"4043_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.oret.2024.10.001","volume":"9","author":"J Hamouz","year":"2025","unstructured":"Hamouz J, Nowosielska A, \u015awi\u0119ch-Zubilewicz A et al (2025) Efficacy and safety of Ranibizumab biosimilar QL1205 in neovascular age-related macular degeneration: a phase III randomized trial. Ophthalmol Retina 9:343\u2013351. https:\/\/doi.org\/10.1016\/j.oret.2024.10.001","journal-title":"Ophthalmol Retina"},{"key":"4043_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","volume":"129","author":"FG Holz","year":"2022","unstructured":"Holz FG, Oleksy P, Ricci F et al (2022) Efficacy and safety of biosimilar FYB201 compared with Ranibizumab in neovascular age-related macular degeneration. Ophthalmology 129:54\u201363. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.031","journal-title":"Ophthalmology"},{"key":"4043_CR27","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.2147\/OPTH.S307746","volume":"15","author":"P Apsangikar","year":"2021","unstructured":"Apsangikar P, Ghadge P, Naik M et al (2021) Randomised, double-blind, comparative clinical study of new Ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. Clin Ophthalmol (Auckl) 15:3087\u20133095. https:\/\/doi.org\/10.2147\/OPTH.S307746","journal-title":"Clin Ophthalmol (Auckl)"},{"key":"4043_CR28","unstructured":"UMIN Clinical Trials Registry (2017) A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration. https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000034245"},{"key":"4043_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.07.015","author":"S Friedman","year":"2025","unstructured":"Friedman S, London N, Hamouz J et al (2025) Randomized trial of biosimilar ABP 938 compared with reference Aflibercept in adults with neovascular age-related macular degeneration. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2025.07.015","journal-title":"Ophthalmol Retina"},{"key":"4043_CR30","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2147\/OPTH.S488866","volume":"18","author":"P Rana","year":"2024","unstructured":"Rana P, Deshmukh H, Shah U et al (2024) Efficacy and safety of biosimilar Ranibizumab (OPTIMAB\u00ae) versus innovator Ranibizumab in patients with neovascular (wet) age-related macular degeneration: a double-blind, randomized, multicenter, phase III study. Clin Ophthalmol (Auckl) 18:3071\u20133081. https:\/\/doi.org\/10.2147\/OPTH.S488866","journal-title":"Clin Ophthalmol (Auckl)"},{"key":"4043_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015804.pub2","author":"T Sunaga","year":"2024","unstructured":"Sunaga T, Maeda M, Saulle R et al (2024) Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD015804.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4043_CR32","doi-asserted-by":"publisher","unstructured":"Sadda SR, Bradvica M, Vajas A, Sagong M, Ernest J, Studni\u010dka J, Veith M, Wylegala E, Patel S, Yun C, Orski M, Astakhov S, T\u00f3th-Moln\u00e1r E, Csutak A, Enyedi L, Choi W, Oh I, Jang H, Woo SJ (2023) Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. BMJ Open Ophthalmol 8(1):e001561. https:\/\/doi.org\/10.1136\/bmjophth-2023-001561","DOI":"10.1136\/bmjophth-2023-001561"},{"key":"4043_CR33","doi-asserted-by":"publisher","unstructured":"Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM (2020) Efficacy and safety of a proposed Ranibizumab biosimilar product vs a reference Ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 139(1):68\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053","DOI":"10.1001\/jamaophthalmol.2020.5053"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04043-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:52:36Z","timestamp":1773996756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04043-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04043-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7909324\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}